Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 FemCap Inc., www.femcap.com  an ... receipt of a patent No: US, 8,795,248 B2 dated ... received FDA clearance in the U.S., 510(K) K121857, medical ... Europe. This patent is related to its menstrual cup with ... company is releasing FemmyCycle Teen, a third menstrual cup ...
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Back in the ... 500 square feet. per employee, which included space for circulation ... then.” says Jeff Howell, partner at Nidea Corporate Real ... in Toronto. “By the year 2000, however, 250 square ... seeing that number come down to 175 to 225 square ...
(Date:9/29/2014)... 2014  Ten of the most highly-respected physicians ... regeneration, allograft reconstruction and research and development, as ... to discuss the future of cartilage regeneration at ... symposium, Cartilage Regeneration: State of the Art ... Minced Juvenile Allograft, and State of the Art ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... DIEGO, Aug. 8 Halozyme Therapeutics, Inc.,(Nasdaq: ... targeting the extracellular matrix, today reported financial,results for ... 2008., "As we,ve previously stated, we continue ... programs that target large markets. Now we are,beginning ...
... -- China Sky One,Medical, Inc. ("China Sky One ... a,manufacturer, marketer and distributor of pharmaceutical, medicinal and,diagnostic ... conduct a,conference call at 10:00 a.m. Eastern Time ... 2008 financial results., Joining Mr. Yan-qing Liu, ...
... 8 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... 30, 2008., Recent Company Highlights, -- Follow-on Biologics ... bioequivalence of INS-19, the ... factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 8Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 9China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 2China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 8Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 9Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 10
(Date:9/30/2014)... conducted by the Ocean Health Index rates the ... overall health. In addition, for the first time, ... ocean regions beyond national jurisdiction (high-seas areas) ... safeguarding biodiversity and providing sustainable food sources. , ... a partnership led by scientists from UC Santa ...
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Salk scientists receive $3 million for BRAIN Initiative grant 2Shape up quickly -- applies to fish, too! 2
... When neurons started dying in Clive Svendsen,s lab dishes, ... cells the same type lost in patients with ... that the University of Wisconsin-Madison stem cell biologist had ... lab, using stem cells derived from a patient. ...
... left Africa over 60,000 years ago in a migration that ... population that exist outside Africa today. Now, researchers ... that exodus. By tracing variations in the X chromosome and ... probably outnumbered women in that migration. The scientists expect that ...
... Deep inside the Frasassi cave system in Italy and more ... ropes of microbes growing in the cold water, according to ... microbiology paradise. Many different types of organisms live in the ... professor of geosciences. "We are trying to map which organisms ...
Cached Biology News:Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3Unusual microbial ropes grow slowly in cave lake 2
...
... is the research-grade spectrofluorometer with a minimum ... S/N ratio 200 or greater for the ... especially designed to keep in mind in ... kinetics, stopped-flow, titration, or anisotropic measurements. ,The ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Arabidopsis microRNA Microarray contains ...
... Microarrays designed for genome-wide microRNA expression profiling ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... microRNA Expression Profiling Service. Probe ... all known cow microRNAs (108 unique mature ...
Biology Products: